Related Experiment Video
Updated: Sep 6, 2025
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.2K
The Utility of Repetitive Cell-Free DNA in Cancer Liquid Biopsies
Ugur Gezer1, Abel J Bronkhorst2, Stefan Holdenrieder2
1Department of Basic Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey.
Diagnostics (Basel, Switzerland)
|June 24, 2022
Summary
Cell-free DNA (cfDNA) in liquid biopsies offers rich pathological information. Analyzing repeat DNA sequences, like ALU and LINE-1 elements, within cfDNA shows promise as a novel cancer biomarker.
Area of Science:
- Biochemistry
- Genomics
- Oncology
Background:
- Liquid biopsy analyzes body fluids for pathological biomarkers.
- Cell-free DNA (cfDNA) is a key focus in liquid biopsy research due to its rich information content.
- cfDNA shows potential in oncology, prenatal testing, and transplant monitoring.
Purpose of the Study:
- To explore the clinical potential of repeat DNA sequences in cfDNA as cancer biomarkers.
- To highlight ALU and LINE-1 elements as underappreciated markers in cancer liquid biopsies.
Main Methods:
- Reviewing research utilizing cell-free repeat DNA sequences.
- Analyzing the overrepresentation of certain repeat families (e.g., pericentric satellites, ALU, LINE-1) in cfDNA.
- Comparing cfDNA repeat abundance to genomic abundance.
Main Results:
- A significant portion of cfDNA consists of repeat DNA sequences.
- Specific repeat families, such as pericentric satellites, ALU, and LINE-1, are overrepresented in cfDNA.
- This overrepresentation suggests potential for novel biomarker development.
Conclusions:
- Repeat DNA elements within cfDNA represent a promising, yet underappreciated, biomarker source.
- Analyzing cfDNA repeat sequences, particularly ALU and LINE-1, could enhance early cancer detection and management.
- Further research into cfDNA repeat elements can expand the cancer liquid biopsy repertoire.
